News & Events

A vaccine for the whole world

Fantastic news for everyone as a vaccine that Symbiosis has supported is hailed as a “vaccine for the whole world”. #Oxford #AstraZeneca #COVID19 #vaccine has 70.4% average efficacy and 90% if a lower dose used – plus it can be stored at normal fridge temperature (2-8 °C).

Symbiosis is proud of its support for the AstraZeneca clinical trials of the AZD1222 vaccine. Part of a world-class team that is leading – and hopefully winning – the global fight against COVID-19. You can read about our involvement here:

Details from The University of Oxford’s, and AstraZeneca plc, interim trial data from its Phase III trials show its candidate vaccine, ChAdOx1 nCoV-2019 (AZD1222) is effective at preventing COVID-19 and offers a high level of protection.

Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said there were: “Benefits for the whole world”. Read more details about the trial results here:

#oxford #astrazeneca #COVID19 #vaccine

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.